ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 30.8% on Friday . The stock traded as high as GBX 5.70 ($0.07) and last traded at GBX 5.10 ($0.06). 10,637,523 shares were traded during mid-day trading, a decline of 51% from the average session volume of 21,499,811 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Up 30.3 %
The company’s 50 day moving average price is GBX 2.39 and its two-hundred day moving average price is GBX 1.93. The firm has a market cap of £21.16 million, a PE ratio of -508.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- The Significance of Brokerage Rankings in Stock Selection
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- What Investors Need to Know About Upcoming IPOs
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
